Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 391.82M P/E 4.09 EPS this Y -160.60% Ern Qtrly Grth -
Income 132.33M Forward P/E -4.25 EPS next Y 3.90% 50D Avg Chg -19.00%
Sales 250.01M PEG - EPS past 5Y - 200D Avg Chg 9.00%
Dividend N/A Price/Book 1.80 EPS next 5Y - 52W High Chg -37.00%
Recommedations 1.70 Quick Ratio 4.89 Shares Outstanding 54.30M 52W Low Chg 89.00%
Insider Own 17.29% ROA 29.87% Shares Float 36.94M Beta 0.95
Inst Own 49.16% ROE 89.61% Shares Shorted/Prior 3.33M/2.26M Price 9.00
Gross Margin 63.13% Profit Margin 52.93% Avg. Volume 670,651 Target Price 17.78
Oper. Margin 60.03% Earnings Date May 7 Volume 260,472 Change -2.17%
About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Voyager Therapeutics, Inc. News
04/22/24 Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
04/16/24 Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
04/09/24 Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
03/30/24 Buy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs.
03/26/24 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/13/24 Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
03/09/24 12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
03/04/24 Analysts Just Made A Major Revision To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Forecasts
02/29/24 Q4 2023 Voyager Therapeutics Inc Earnings Call
02/29/24 Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript
02/28/24 Voyager Therapeutics Inc (VYGR) Announces Strong Year-End Financials with Significant Cash Position
02/28/24 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
02/26/24 Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
02/26/24 Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?
02/21/24 Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
02/20/24 Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
02/07/24 Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
01/26/24 While institutions own 30% of Voyager Therapeutics, Inc. (NASDAQ:VYGR), individual investors are its largest shareholders with 42% ownership
01/11/24 Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024
01/04/24 Voyager Therapeutics Announces Pricing of Public Offering
VYGR Chatroom

User Image UncleStock Posted - 4 hours ago

$SIGA $INVA $AMLX $VYGR suggested for $NBI US NASDAQ Biotechnology - value screen: https://zpr.io/tBVec

User Image TomMac64 Posted - 1 day ago

$VYGR if you look at daily I see shorts covering ?

User Image TomMac64 Posted - 1 day ago

$VYGR Based on nothing !

User Image Dupsy Posted - 1 day ago

$VYGR going to $13 by eow, $24 after this presentation. Buy now! https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-present-broad-set-translational-data

User Image Stock_Titan Posted - 2 days ago

$VYGR Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting https://www.stocktitan.net/news/VYGR/voyager-therapeutics-to-present-broad-set-of-translational-data-wb4odbbsvc0q.html

User Image DnFkWtMe Posted - 5 days ago

$VYGR are you fckn kidding me What the hell happened to this pos? 🤦🏻‍♂️ loaded to early themmmm

User Image UncleStock Posted - 5 days ago

$SIGA $INVA $AMLX $VYGR suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

User Image JE_CC Posted - 1 week ago

$VYGR

User Image briefingcom Posted - 1 week ago

$VYGR: Voyager Therapeutics announces that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240416071010VYGR&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image TomMac64 Posted - 1 week ago

$VYGR Bullish news don’t know why nobody knows this stock exists ? Tiny debt and a lot of cash great science and very good management sounds like a recipe for success ?

User Image DonCorleone77 Posted - 1 week ago

$VYGR $NBIX Voyager announces selection of development candidate for GBA1 Program Voyager Therapeutics (VYGR) announced that the joint steering committee with its collaborator Neurocrine Biosciences (NBIX) has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson's disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager's TRACER capsid discovery platform. The companies expect to file an Investigational New Drug application with the FDA for the program in 2025. Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the second quarter of 2024. Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program. The GBA1 program is being developed under the 2023 strategic collaboration agreement between Voyager and Neurocrine Biosciences for research, development, manufacture, and commercialization of certain AAV gene therapy products for programs targeting Parkinson's disease and other GBA1-mediated diseases and three other undisclosed programs to address central nervous system diseases or conditions associated with rare genetic targets. Under the terms of the 2023 collaboration agreement, Voyager is eligible to receive up to $1.5 billion in potential development milestone payments, as well as additional commercial milestone payments, tiered royalties on net sales, and program funding. Voyager maintains an option to elect 50/50 cost- and profit-sharing in the U.S. for the GBA1 program following topline data from the first Parkinson's disease clinical trial.

User Image Stock_Titan Posted - 1 week ago

$VYGR Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment https://www.stocktitan.net/news/VYGR/voyager-therapeutics-announces-selection-of-development-candidate-er5b100ln0k5.html

User Image dojidad Posted - 1 week ago

$VYGR Sometimes I wonder about myself. I took a position on the 1st but look at the divergence. There was a uptrend at the same time the RSI was in a downtrend. That's called divergence and there is no way in H E double toothpicks I should have taken a position without some sort of confirmation that was going to turn around, but I did, and lost money. Oh well, hopefully somebody reading this will think twice when they see that and won't do what I did. I post my success but also my failures so I can learn and be better. Have a terrific day!

User Image Aigner_Andreas Posted - 1 week ago

TD BUY $VYGR at 8.43, Supp 8.43 Resis 10.54 R25 HiLo 28% T1Y 7 buy 2.3 DIV N/A #Voyager Th #stocks #trading #finance #market

User Image DnFkWtMe Posted - 1 week ago

@Redposition $VYGR - criminal what the MM/Specialist are doing, lowering the price on measly 400 share trades and scaring the retail investors on margin ... VYGR's fundamentals don't justify this range ... total donuts.... see you back at $10 by Friday

User Image Redposition Posted - 2 weeks ago

$VYGR Junk of the junk !

User Image UncleStock Posted - 2 weeks ago

$SIGA $INVA $VYGR $HRMY suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

User Image JE_CC Posted - 2 weeks ago

User Image commoncentsinvestor Posted - 2 weeks ago

$VYGR SMALL CAP INVESTORS Anyone looking for a stock that could have a big increase in share price in 2024 might want to take a look at CVRX. They got FDA approval for its Barostim product to improve the lives of people suffering from heart failure back in 2019. They have spent the last 4 years building a market for their product and it is about to reap big rewards. They have been increasing their revenues, the number of implant centers, their territories, , and their public visibility by leaps and bounds and work on 84% gross margins. This should all result in big increases in revenues and share price this year. I expect a minimum of $65M in 2024 revenues and with 84% Gross Margins, a 15 times Market Cap would be very reasonable. That would put the share price at about $47. Current Share Price is under $18. With only 600 followers on Stock Twits, it is very early in the game for folks who like to invest in under followed small companies with HUGE potential.

User Image kiwiSurfer Posted - 2 weeks ago

@Herr_Chicken @WNTCT recall that $VYGR cut a Big Deal in January 24 with upfront and residuals for a far INFERIOR capsid (100M upfront). I see a STAC-BBB Deal obviate all this speculation and render it irrelevant. $LLY $BIIB or another Big Pharma will see the potential CNS Goldmine in plain view.

User Image Aigner_Andreas Posted - 2 weeks ago

#GoldenCross $VYGR at 9.35 R7 HiLo 40% T1Y 7 buy DIV N/A #Voyager Th #stocks #trading #finance #market

User Image NYBomba Posted - 2 weeks ago

$VYGR - New CFO https://biography.omicsonline.org/united-states-of-america/sanofi-genzyme/robin-swartz-1993035

User Image NYBomba Posted - 2 weeks ago

$VYGR - Voyager Therapeutics’ CFO, Peter P. Pfreundschuh, has agreed to a transition and separation plan, stepping down from his role and all related positions by May 5, 2024. He will remain as Senior Financial Advisor during this transition, continuing to earn his current salary and benefits. Afterward, he’ll provide consulting services until at least June 28, 2024, with the potential for extension. His stock awards will vest during this consulting period, and he’ll have six months post-consultancy to exercise vested options. Concurrently, Robin Swartz has been appointed as the new principal financial and accounting officer, bringing her extensive experience from Genzyme and Sanofi to the role.

User Image NYBomba Posted - 3 weeks ago

$VYGR - criminal what the MM/Specialist are doing, lowering the price on measly 400 share trades and scaring the retail investors on margin ... VYGR's fundamentals don't justify this range ... total donuts.... see you back at $10 by Friday

User Image Stockbricks Posted - 3 weeks ago

$VYGR why did CFO resign or made to resign? crappy stock

User Image NYBomba Posted - 3 weeks ago

$VYGR - looks like we'll see the Golden Cross in action tomorrow, let's hope for an overall market reversal, hopefully it'll add to the GCross push .... Peace

User Image UncleStock Posted - 3 weeks ago

$SIGA $INVA $VYGR $AMLX suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

User Image GSP Posted - 3 weeks ago

$SOL $CRDF $VYGR $STOK $CXAI

User Image GSP Posted - 3 weeks ago

This $VYGR chart is interesting. We will be watching it in chat tomorrow.

User Image GSP Posted - 3 weeks ago

Trading Watch List Video for April 2nd (con't): $CRDF $SOL $VYGR $CXAI $STOK Watch here: https://greatstockpix.com/april-2nd-day-trading-watch-list/

Analyst Ratings
Guggenheim Buy Mar 26, 24
HC Wainwright & Co. Buy Mar 19, 24
Citigroup Buy Mar 7, 24
Wells Fargo Overweight Jan 2, 24
Oppenheimer Outperform Aug 7, 23
Canaccord Genuity Buy May 10, 23
Truist Securities Buy May 10, 23
Oppenheimer Outperform Mar 10, 23
Chardan Capital Neutral Nov 3, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PFREUNDSCHUH PETER P. Chief Financial Offi.. Chief Financial Officer Oct 03 Sell 6.99 13,567 94,833 149,433 10/05/23
Carter Todd Alfred Chief Scientific Off.. Chief Scientific Officer Sep 15 Sell 8.16 10,500 85,680 54,360 09/18/23
Carter Todd Alfred Chief Scientific Off.. Chief Scientific Officer Sep 15 Option 2.85 5,000 14,250 64,860 09/18/23
Carter Todd Alfred Chief Scientific Off.. Chief Scientific Officer Jul 06 Sell 10.80 5,500 59,400 59,860 07/10/23
Sandrock Alfred President and CEO President and CEO Apr 03 Sell 7.83 7,437 58,232 214,618 04/05/23
NEUROCRINE BIOSCIENCES INC 10% Owner 10% Owner Feb 23 Buy 8.88 4,395,588 39,032,821 8,575,316 02/24/23
Hesslein Robert W. Senior VP & General.. Senior VP & General Counsel Feb 17 Sell 7.45 3,297 24,563 106,610 02/22/23
Carter Todd Alfred Chief Scientific Off.. Chief Scientific Officer Feb 17 Sell 7.45 738 5,498 67,553 02/22/23
Carter Todd Alfred Chief Scientific Off.. Chief Scientific Officer Feb 13 Sell 7.67 797 6,113 34,291 02/15/23
Hesslein Robert W. Senior VP & General.. Senior VP & General Counsel Feb 13 Sell 7.67 2,868 21,998 109,907 02/15/23
Third Rock Ventures III, L.P. 10% Owner 10% Owner Jan 30 Sell 9.2 388,642 3,575,506 4,685,291 02/01/23
Third Rock Ventures III, L.P. 10% Owner 10% Owner Jan 24 Sell 9.25 150,000 1,387,500 5,123,933 01/26/23
Third Rock Ventures III, L.P. 10% Owner 10% Owner Jan 20 Sell 9.11 155,000 1,412,050 5,273,933 01/24/23
EcoR1 Capital, LLC 10% Owner 10% Owner Jan 09 Sell 8.07 902,400 7,282,368 3,851,507 01/11/23
PIERCE GLENN Director Director Jul 14 Sell 6.70 9,512 63,730 16,788 07/18/22
Higgins Michael J Director Director Jul 14 Sell 6.70 13,891 93,070 31,314 07/18/22
EcoR1 Capital, LLC 10% Owner 10% Owner Jun 21 Buy 5.47 477,400 2,611,378 4,753,907 06/23/22
Swartz Robin Chief Operating Offi.. Chief Operating Officer Apr 04 Sell 8.25 1,527 12,598 52,060 04/06/22
Hesslein Robert W. Senior VP & General.. Senior VP & General Counsel Apr 04 Sell 8.25 2,786 22,984 114,963 04/06/22
Swartz Robin Chief Operating Offi.. Chief Operating Officer Mar 21 Sell 8.49 4,413 37,466 53,587 03/23/22
Hesslein Robert W. Senior VP & General.. Senior VP & General Counsel Mar 21 Sell 8.49 4,955 42,068 117,749 03/23/22
Burek Julie VP, Finance VP, Finance Mar 21 Sell 8.49 2,649 22,490 52,458 03/23/22
Burek Julie VP, Finance VP, Finance Jan 03 Sell 2.95 3,328 9,818 46,257 01/14/22